The short version.
MOTS-c is one of a handful of known mitochondrial-derived peptides (MDPs) — peptides encoded by mitochondrial DNA that act as signaling molecules between mitochondria and the rest of the cell (mitokines). The longevity interest in MOTS-c rests on the broader recognition that mitochondrial dysfunction is a hallmark of aging, and that mitokines may participate in the inter-organ signaling that calibrates metabolic and stress responses across tissues.
Circulating MOTS-c levels appear to decline with age in some studies. In aged mice, exogenous MOTS-c improves exercise capacity, insulin sensitivity, and several markers of metabolic health. That makes it part of the mitochondrial-aging conversation alongside NAD+, sirtuins, and AMPK-pathway interventions.
What the literature actually says.
Strongest signal: aged mice on MOTS-c show improved healthspan markers — running capacity, insulin sensitivity, body composition under metabolic stress. The mechanism (AMPK activation, mitochondrial efficiency, glucose handling) is consistent with what an anti-aging metabolic peptide would mechanistically need to do.
Weaker signal: human longevity data. There are observational correlations — lower MOTS-c in older adults, in some metabolic disease states — but no human RCT showing MOTS-c slows aging biomarkers or extends healthspan. The mitochondrial-peptide field is young.
The honest framing: MOTS-c sits in the "biologically interesting, mechanistically grounded, clinically early" tier of longevity peptides. The rationale is real. The proof is preliminary. People using it for longevity are running a personal experiment with a plausible mechanism — which is fine, as long as it's labeled accurately.
MOTS-c is biologically interesting, mechanistically grounded, and clinically early. That's exactly what most longevity peptides actually are.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Where does MOTS-c sit in our overall longevity plan — primary or adjunct?
- What biomarkers (metabolic, inflammatory) would we track over time?
- How does MOTS-c interact with the rest of the program (sleep, training, lipids)?
- What's a sensible trial period before reassessing?
- If response is unclear, what's our off-ramp?
Sources